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Background: The prevalence of substance use in people acutely admitted to in-patient psychiatric wards is high
and the patients` duration of stay is limited. Motivational interviewing is a method with evidence based effect in
short interventions. The aims of the present study were to compare the effects of 2 sessions of motivational
interviewing and treatment as usual (intervention group) with treatment as usual only (control group) on adult
patients with comorbid substance use admitted to a psychiatric in-patient emergency unit.
Methods: This was an open randomised controlled trial including 135 patients where substance use influenced the
admittance. After admission and assessments, the patients were allocated to the intervention group (n = 67) or the
control group (n = 68). The primary outcome was self-reported days per month of substance use during the last
3 months at 3, 6, 12 and 24 months after inclusion. Data was analysed with a multilevel linear repeated measures
regression model.
Results: Both groups reduced substance use during the first 12 months with no substantial difference between the
2 groups. At 2 year follow-up, the control group had increased their substance use with 2.4 days (95% confidence
interval (CI) –1.5 to 6.3), whereas the intervention group had reduced their monthly substance use with 4.9 days
(95% CI 1.2 to 8.6) compared to baseline. The 2 year net difference was 7.3 days of substance use per month (95%
CI 1.9 to 12.6, p < 0.01) in favour of the intervention group.
Conclusions: The present study suggests that 2 sessions of motivational interviewing to patients with comorbid
substance use admitted to a psychiatric emergency unit reduce substance use frequency substantially at 2 year
follow-up.
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Patients with psychiatric disorders have higher rates of
substance use disorders than the general population [1].
Among patients acutely admitted to psychiatric in-
patient wards the use of alcohol and illicit drugs is high
[2]. Proportions of substance use disorders in these pa-
tients range from 32 to 56% in previous studies [3,4]. In
some studies on patients with psychiatric disorders, al-
cohol and drug use are found to be associated with more
severe symptoms, poorer treatment adherence [5-7] and
a higher risk of relapses and admissions [8]. Patients
with substance use have a short length of stay in psychi-
atric emergency units [9,10], giving limited time for
treatment interventions. Suitable treatments to prevent
recurrence of problematic substance use after detoxifica-
tion and discharge are therefore needed.
Motivational interviewing developed by William R.
Miller and Stephen Rollnick [11], is a directive, client-
centered method for enhancing intrinsic motivation to
change by exploring and resolving ambivalence, increas-
ing the patients` own view of the importance of change
and emphasizing the patients` freedom of choice. The
method has been applied in a wide variety of settings
and includes different health behaviours [12]. A recent
Cochrane review concludes that motivational interviewing
has a significant effect on substance use when compared
to no treatment, but no difference compared to treatment
as usual. The effects tend to be seen early but diminish
during one year follow-up [13]. Studies with a follow-up
longer than 12 months are sparse [14,15]. Interestingly, a
study has shown that psychotherapy inducing intrinsic
change and insight actually has been shown to have clin-
ical effect after two years [16].
The documentation of the effect of motivational
interviewing on patients with combined substance use
and psychiatric disorders is inconclusive [17-20]. Motiv-
ational interviewing is often integrated in combined psy-
chosocial interventions [21] and studies include mainly
patients with severe mental illnesses (e.g. psychoses)
[22,23] ignoring the major group with combined sub-
stance use and affective disorders.
Randomised controlled trials with long term follow-up
on manual-guided psychosocial interventions to patients
with substance use and co-occurring depression, anxiety
or psychotic disorders are few [24,25].
The aims of the present open randomised controlled
trial were to investigate the effects of individually ad-
ministered motivational interviewing on patients with
comorbid substance use admitted to a psychiatric emer-
gency unit. We hypothesized that the patients receiving
both motivational interviewing and treatment as usual
would reduce the frequency of substance use after dis-
charge more than the patients receiving treatment as
usual only.Methods
Study design and randomisation
This study was a stratified randomised controlled open
clinical trial, where consecutive patients were allocated
either to the combination of motivational interviewing
and treatment as usual (intervention group), or treat-
ment as usual only (control group).
Ethics
The study was approved by the Regional Committee for
Medical Research Ethics, (identification number 110–04)
Middle Norway and Norwegian Social Science Data
Services (NSD).
Participants
At the time of the inclusion, St. Olav University Hos-
pital, Østmarka Department of Psychiatry was the only
emergency psychiatric in-patient service for adult pa-
tients from 18 years old in a catchment area of about
140 000 inhabitants from a geographical area covering
50% of the population of the city of Trondheim and the
surrounding rural areas. About 700 patients were admit-
ted every year.
Participants were patients consecutively admitted to
the 2 emergency units in the hospital during the study
period from October 2004 to December 2005 except
three short breaks during vacations, totally 9 weeks.
Eligible participants were patients who on admittance
fulfilled at least one of the following criteria: They were
considered clinically to be under the influence of either
substance(s), benzodiazepine(s) not used as prescribed
by a physician, or the patient`s substance use was con-
sidered to affect the actual admission. Also patients ini-
tially answering negatively regarding substance use were
included if they tested positively for one or more sub-
stances in an on-site urine drug of abuse screening test
and they then confirmed such substance use. Finally pa-
tients not fulfilling the above criteria but who had re-
ceived treatment for substance use the last 2 years prior
to admission were included. This inclusion procedure
was conducted to allow a possibility to intervene before
discharge as this group of patients often has a short dur-
ation of stay. The final diagnoses according to ICD-10
were set at discharge with maximal information about
the patients during the stay, i.e. after inclusion, random-
isation and intervention. Thus, some of the participants
may have been included in the study without fulfilling
the ICD-10 criteria for disorders due to psychoactive
substance use.
Patients were excluded if they were mentally retarded,
suffering from dementia, serious brain damage or other
conditions where adequate verbal communication was
impossible. Patients were also excluded if they spoke nei-
ther Norwegian nor English. Finally, patients evaluated to
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severe psychosis symptoms) were excluded. The senior
consultants at the department considered the inclusion
and exclusion criteria for each patient.
Procedure and assessments
At admittance all patients were examined by a physician.
General clinical-chemical blood tests and an on-site urine
screening-test for drug use (AccuSign DOA 5, Princeton
Bio-Meditech Corporation, Princeton, NJ) were routine
procedures at the department. AccuSign DOA 5 is an im-
munoassay urine test with acceptable reliability [26] for the
qualitative detection of amphetamine, benzodiazepines,
cannabis, cocaine and opiates and/or their metabolites.
Also, all patients were assessed with Global Assessment of
Functioning Scale [27], Split Version [28] at admittance.
In addition to clinical history, the patients were asked
to fill in a self-report questionnaire. This questionnaire
was used for baseline and follow-up assessments and de-
scribed the frequency of alcohol and substance use and
use of benzodiazepines not used as prescribed from a
physician. The frequency as a measure of substance use
severity was considered an adequate measure in this
population with excessive substance use according to the
eligible criteria. The frequency of substance use also will
be related to function in general. The questionnaire has
not been assessed for validity or reliability.
For the last three months prior to admission the re-
spondents were asked to categorize their use of alcohol,
cannabinoids, amphetamine, opiates, benzodiazepines,
ecstasy and other substances respectively into 7 possible
categories: never, monthly or more seldom than monthly,
2–3 times monthly, once a week, 2–3 days a week, 4–6
days a week and every day. The seven categories were
recoded to correspond to number of days per month:
never (0 days), monthly or more seldom than monthly
(1 day), 2–3 times monthly (2.5 days), once a week (4.3
days), 2–3 days a week (10.7 days), 4–6 days a week (21.4
days) and every day (30 days).
For patients fulfilling the eligible criteria, a full de-
scription of the study procedure was given orally and
written to each participant before written informed con-
sent was obtained prior to inclusion and randomisation.
We expected different effect-sizes of the intervention
according to different psychiatric clinical characteristics
of the patients. Thus the patients were stratified into 3
groups based on the information available at the time of
inclusion: non-psychosis and substance use, psychosis
and substance use or non-psychosis and use of benzodi-
azepines not as prescribed by a physician and no other
substance use.
The patients were randomly assigned to either the
intervention group or the control group. Randomisation
was performed by a web-based system developed andadministered by the Unit of Applied Clinical Research,
Institute of Cancer Research and Molecular Medicine,
Norwegian University of Science and Technology,
Trondheim, Norway. This was a block randomisation,
with the block size for all 3 strata set to 10 in each strata
group. The randomisation logarithm was programmed
in PHP with a My SQL database. The clinicians making
the baseline assessments had no information regarding
the block size used for randomisation.
Intervention; motivational interviewing
The intervention consisted of 2 sessions manual guided
motivational interviewing delivered individually to the
patients by a trained therapist [11]. The manual was de-
veloped by two motivational interviewing trainers in co-
operation with the first author of this manuscript. Each
session was planned to last 45 minutes. Depending on
the patients` length of stay in the hospital, the second
session took place on another day or later the same day.
In the first session the patients` ambivalence to sub-
stance use was explored. Also the severity of the pa-
tients` substance use was considered. In the second
session the patients` experiences of substance use and
prior attempts to change were explored to build intrinsic
motivation for change. Actual readiness for change in
substance use patterns and commitment to a change
plan were focused on. The intervention was delivered in
a motivational interviewing style. If they wanted, patients
received information about, and referral to available
follow-up treatment programs for substance use. The
interviewer offered a written summary from the 2 ses-
sions to each patient.
Treatment as usual
Treatment as usual was individualized according to the
clinical condition of the patients during the stay and in
accordance with general national and international med-
ical standards. It would usually include detoxification,
pharmacotherapy, and general psychotherapy. Also, treat-
ment would be given for any coexisting non-substance-re-
lated disorder, including psychiatric disorders.
General information about the harmful effects of
substances and suggestions regarding treatment for sub-
stance use, including possible referral to specialty sub-
stance use treatment institutions, would be given.
Planning of discharge with referral to out-patient and
primary community health care after discharge usually
would be included.
Training and supervision of physicians and psychologists
A total of 15 therapists at the hospital fulfilled a training
programme consisting of workshops and videotaping of
role play using the manual with individual feedback on
motivational interviewing micro-skills before the study
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study period.
Diagnoses
The patients’ psychiatric diagnoses were set at discharge
from the department according to the ICD-10 Diagnostic
criteria for research [29] in a consensus meeting by the
department staff, including at least 2 senior consultants.
Primary outcome: substance use
The primary outcome was days per month of substance
use the last 3 months. The most frequently used sub-
stance was measured. In the follow-up, questionnaires
were sent by mail to the patients 3, 6, 12 and 24 months
after inclusion. As compensation for participation, the
patients received a lottery ticket worth 3 GBP for each
questionnaire returned. If we did not receive the ques-
tionnaire during the following 14 days, nurses from the
department, blind to treatment allocation, made tele-
phone calls to ask for patients` reply.
Based on the size of previous studies at the time of the
study period [30,31], we planned to include 100 patients
in each trial arm. Since the recruitment was slower than
anticipated, we ended the inclusion period when 135 pa-
tients were included in total.
Statistical methods
The descriptive characteristics of the sample were gener-
ated using SPSS for windows version 17. The estimation
of the intervention effect was performed according to
the intention-to-treat principle. A multilevel linear re-
peated measures regression model with random slopes
was used for analyses in STATA 11 for windows (Stata
Corp., College Station, TX). This approach uses all avail-
able information and is less susceptible to bias under the
assumption of missing at random [32,33]. Each follow-up
wave was added to the model as a dummy variable (i.e. 3 -
months, 6 months, 12 months, 24 months and the admit-
tance registration as a reference). To assess differences
between intervention and control during follow-up, inter-
action terms between the intervention and each registra-
tion time-point were included in the model. In an
additional analysis we also tested a model which included
those participants with complete registrations of substance
use frequency on all follow-up time points. As an indica-
tor of substance use clustering at the patient level, we esti-
mated an Intra class correlation coefficient (ICC) [32]. As
a sensitivity analysis, we adjusted for gender, age and the
Global Assessment of Functioning Scale, [27] Split Ver-
sion [28] score at admittance. Furthermore, we performed
an analysis using frequency of alcohol use as the outcome,
and an analysis where the outcome measure was calcu-
lated without the use of benzodiazepines. Finally, we
analysed on the number of daily doses within 30 days,where daily doses is defined as the sum of the number of
days of use for all substances combined in each individual.
Results
Participants
Recruitment and attrition according to CONSORT
guidelines [34] are presented in Figure 1.
From a total of 835 admittances representing 518
patients, 293 patients had no known substance use. Of
the 225 patients with substance use, 90 were excluded
according to the exclusion criteria. Thus, a total of 135
patients were stratified and randomly allocated, 68 pa-
tients to the control group and 67 patients to the inter-
vention group. A urine sample for on-site drugs of abuse
screening-test was obtained from 122 of the 135 patients.
Baseline characteristics are presented in Table 1. The
patients` mean age was 36.5 years (SD = 13.7), ranging
from 18 to 80 years old. They were predominantly men,
tended to be single and receiving disability payment and
living in their own homes. According to Global Assess-
ment of Functioning Scale, Split Version, the mean gen-
eral functioning score of the patients was 43.1 (SD = 8.4,
range 22–65), and the mean general symptom score
were 41.4 (SD = 9.4, range 5 – 65).
Substance use at baseline
Alcohol was the most frequently used substance, with 55
patients reporting use in both the intervention and the
control group respectively (Table 2). Mean monthly days
of use for most frequently used substance the last 3
months were 13.6 days (SD = 10.7) in the intervention
group and 11.7 days (SD = 9.9) in the control group.
Psychiatric diagnoses
The primary diagnoses at discharge were substance use
disorders in 58 (43.0%) patients, affective disorders in 46
(34.1%), psychotic disorders in 8 (5.9%) and other disor-
ders in 23 (17.0%) patients respectively. Of the 135 pa-
tients, a total of 117 (86.7%) patients had at least one
substance use diagnosis. Among the substance use diag-
noses, 6 (5.1%) patients had psychotic disorder due to
psychoactive substance use, 61 (52.1%) had dependence
syndrome, 46 (39.3%) harmful use and 4 (3.4%) acute in-
toxication. The median days of hospitalization for the
intervention group was 6 (range 0–854, Q1: 3, Q3: 20),
and for the control group 5 (range 0–886, Q1: 3, Q3: 10)
respectively. Mann Whitney showed no statistical signifi-
cant difference in days of hospitalization between the
intervention group and the control group (p = 0.5).
Intervention
Of the 67 patients allocated to motivational interviewing,
55 (82.0%) completed both sessions separately. 11 (16.4%)
All admittances (n=835)
Number of patients (n=518)
Excluded (n=383) 
 Did not meet substance use criteria (n=293) 
 Patients with substance use not included (n=90): 
  Too sick to participate (n=25) 
  Did not want to participate (n=26) 
  Short stay/procedure not fulfilled (n=25) 
  Organic disorder (n=9)
  Did not speak Norwegian nor English /other reasons (n =5) 
Allocated to control group (treatment as usual) 
(n=68)  
Allocated to intervention group (motivational 
interviewing and treatment as usual) (n=67): 
Completed therapy in 2 sessions (n=55)  
Completed therapy in 1 session (n=11)  
Received only first session (n=1)
Included and stratified (n=135): 
Psychiatric disorder and substance use (n=119) 
Psychotic disorder and substance use (n=9)
Psychiatric disorder and use of benzodiazepines not as prescribed from physician (n=7) 
Primary outcome analysed at 3 months (n=46) 
No response (n=18) 
Lost to follow up cumulative (n=4): 
 Died (n=0) 
 Did not want to answer questionnaire (n= 4) 
Primary outcome analysed at 3 months (n=53) 
No response (n=12) 
Lost to follow up cumulative (n=2): 
 Died (n= 1) 
 Did not want to answer questionnaire (n=1) 
Primary outcome analysed at 24 months (n=33) 
No response (n=26) 
Lost to follow up cumulative (n=9): 
 Died (n=2) 
 Did not want to answer questionnaire (n=7) 
Primary outcome analysed at 24 months (n=39) 
No response (n=19) 
Lost to follow up cumulative (n=9): 
 Died (n=2) 
 Did not want to answer questionnaire (n=7) 
Randomised (n=135)
Primary outcome analysed at 6 months (n=45) 
No response (n=19) 
Lost to follow up cumulative (n=3): 
 Died (n=1) 
 Did not want to answer questionnaire (n=2) 
Primary outcome analysed at 6 months (n=39) 
No response (n=23) 
Lost to follow up cumulative (n=5): 
 Died (n=0) 
 Did not want to answer questionnaire (n=5) 
Primary outcome analysed at 12 months (n=49) 
No response (n=12)  
Lost to follow up cumulative (n=6): 
 Died (n=2) 
 Did not want to answer questionnaire (n=4)
Primary outcome analysed at 12 months (n=41) 
No response (n=20): 
Lost to follow up cumulative (n=7):  
 Died (n=2) 
 Did not want to answer questionnaire (n=5) 
Figure 1 Recruitment and attrition according to CONSORT guidelines.
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ously with no time in between. One patient did not want
the second session. Some patients did not want a written
summary. Of the 55 patients completing both sessions 2
received the second session as out-patients after discharge.
Median days from admittance to the first intervention
were 2.0 (range 0–35) and mean duration of the total in-
terventions was 82.8 minutes (SD = 26.5) with a minimum
of 35 and a maximum of 150 minutes.
By accident, one patient was included and given inter-
vention twice, with 90 days between interventions. Weused the patients` first intervention and disregarded the
other.
Follow-up and attrition
Follow-up questionnaires were completed by 99 (73.3%)
patients at 3 months, by 84 (62.2%) at 6 months, by 90
(66.7%) at 12 months and by 72 (53.3%) at 24 months
(Figure 1). Response during follow-up was assessed with
a random intercept logistic regression model. We found
lower response during follow up for the control group
compared with the intervention group (odds ratio 0.5,
Table 1 Baseline characteristics
Intervention group N (%) Control group N (%) p-value a
Male 38 (56.7) 40 (58.8) 0.941
Single, separated or widow 52 (77.6) 52 (76.5) 1.000
Receiving disability payment, pensions or benefits 48 (71.6) 54 (79.4) 0.395
No housing, institution or hospice 8 (11.9) 14 (20.6) 0.260
Education 0.506
<10 years of schooling 20 (29.9) 20 (29.4)
10-12 years of schooling 29 (43.3) 35 (51.5)
>12 years of schooling 18 (26.9) 13 (19.1)
Admitted by coercion 8 (11.9) 9 (13.2) 1.000
Mean (SD) Mean (SD) p-value b
Age 36.9 (14.0) 36.1 (13.4) 0.728
Global Assessment of Functioning Scale, Split Version, Symptom score 41.9 (9.2) 40.9 (9.7) 0.517
Global Assessment of Functioning Scale Split Version, Function score 43.6 (8.4) 42.5 (8.4) 0.457
a χ 2 –test.
b independent –samples t-test.
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24 months follow-up, were compared regarding baseline
substance use, gender, age, housing, marital status, edu-
cational level and Global Assessment of Functioning
scale, Split version, with no statistical significant differ-
ences between the groups, other than a difference in in-
come, showing a higher proportion of the responders
having work or student loans as an income, than the
non-responders (p = 0.02).
Primary outcome
There was considerable clustering of substance use at
the patient level as indicated with an ICC of 0.25. Both
the intervention and the control groups showed similar
reductions in days of substance use the first 12 months
(Figure 2 and Table 3). At 12 months the control group
had reduced their average substance use with 3.6 days
(95% CI 0.3 to 6.9), while the intervention group had re-
duced their substance use with 5.4 days (95% CI 2.4 to
8.5) - a net difference in reduction between the groupsTable 2 Mean number of days of monthly substance use the
Intervention group (n = 67)
Answereda N Number of days, mean(SD) Any use
Alcohol 60 10.4 (9.4) 55 (9
Amphetamine 67 1.4 (5.3) 11 (1
Benzodiazepines 63 2.4 (5.6) 17 (2
Cannabinoids 67 5.1 (9.7) 27 (4
Ecstasy 66 0.0 (0.4) 0 (0
Opioids 66 1.7 (6.3) 7 (10
Main substanceb 67 13.6 (10.7)
a Number of patients answering the questionnaire about the actual substance.
b The substance most frequently used.of 1.8 days (95% CI −2.7 to 6.3). At 2 year follow-up, the
control group had increased their substance use with
2.4 days (95% CI −1.5 to 6.3), whereas the intervention
group had reduced their monthly substance use with
4.9 days (95% CI 1.2 to 8.6) compared to baseline. The
net difference from baseline to 2 year follow-up was 7.3
days (95% CI 1.9 to 12.6, p < 0.01) in favour of the inter-
vention group. In additional analysis we adjusted for
gender, age and baseline Global Assessment of Function-
ing Scale Split Version, but this did not substantially
change the results.
An analysis comprising only alcohol use showed simi-
lar results as the main analysis (see Additional file 1:
Table S1). Both groups reduced number of days using al-
cohol in the first year. At 12 months the control group
had reduced their average alcohol use with 3.7 days
(95% CI 1.0 to 6.4), while the intervention group had re-
duced their alcohol use with 4.0 days (95% CI 1.5 to
6.4). At 24 months of follow-up, the control group had
increased their alcohol use with 0.9 days monthly (95%last 3 months reported at baseline
Control group (n = 68)
N (%) Answereda N Number of days, mean(SD) Any use N (%)
1.7) 57 10.1 (8.3) 55 (96.5)
6.4) 66 1.0 (3.6) 15 (22.7)
7.0) 59 1.6 (5.6) 9 (15.3)
0.3) 66 3.0 (7.3) 18 (27.2)
.0) 64 0.1 (0.4) 4 (6.3)
.6) 64 1.1 (5.3) 8 (12.5)
66 11.7 (9.9)
Figure 2 Estimated days per month of substance use the last 3 months. With 95% confidence intervals (vertical lines) as a function of
months from baseline. Estimates based on a linear mixed model.
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tion group had reduced their alcohol use with 3.8 days
per month (95% CI 0.9 to 6.7) in the same period. There
was a net difference in use of alcohol from baseline to
24 months between the intervention and the control
group of 4.7 days per month (95% CI 0.4 to 9.0).
A model without self-reported use of benzodiazepines,
showed similar results as reported in Figure 2 (see Add-
itional file 2: Table S2). Both the intervention and the
control group reduced the number of monthly days with
substance use the last 3 months the first year. After 12
months the control group showed a reduction of 4.5 days
(95% CI 1.7 to 7.3), while the intervention group had re-
duced their substance use with 6.2 days (95% CI 3.6 to
8.8). At 24 months of follow-up the control group hadTable 3 Difference in substance use the last 3 months accord
Intervention compared with control at start of treatment
Time 3 months compared with start of treatment b
Time 6 months compared with start of treatment b
Time 12 months compared with start of treatment b
Time 24 months compared with start of treatment b
Time 3 months a Intervention c
Time 6 months a Intervention c
Time 12 months a Intervention c
Time 24 months a Intervention c
Constant
Estimated days per month with 95% confidence intervals, using a linear mixed mod
a Unstandardized regression coefficient.
b Estimate for the control group.
c Estimate for additional effect of time for the intervention group compared with thdecreased their use by 0.5 days (95% CI −2.8 to 3.7) com-
pared with start of treatment, while the intervention group
showed a reduction of 6.2 days (95% CI 3.2 to 9.3).
Analysing the number of daily doses including all sub-
stances each patient used, not only the main substance
for each patient, showed similar results (see Additional
file 3: Table S3). Both groups reduced substance use the
first 12 months, while the control group was close to the
baseline substance use at 24 months – an increase of
0.2 days (95% CI −5.5 to 6.0) compared with baseline.
The intervention group reduced the number of daily
doses of substances per month with 9.4 daily doses (95%
CI 3.9 to 14.9) from baseline to 24 months. Excluding
benzodiazepines from the analysis did not alter these
results.ing to time and intervention
βa 95% CI p-value
1.88 −1.50 to 5.22 0.271
−4.13 −7.17 to −1.10 0.008
−3.24 −6.46 to −0.02 0.049
−3.59 −6.85 to −0.34 0.030
2.37 −1.54 to 6.28 0.235
1.18 −3.00 to 5.35 0.580
−1.28 −5.71 to 3.15 0.571
−1.81 −6.27 to 2.65 0.425
−7.26 −12.64 to −1.89 0.008
11.72
el.
e control group relative to start of treatment.
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reported in Figure 2 (see Additional file 4: Table S4), but
the precision of the estimates was considerably reduced.
Compared with baseline the control group had 0.7 more
days (95% CI −5.0 to 6.5) with substance use at 24
months of follow-up, while the intervention group had
reduced their number of days with substance use with
2.4 days (95% CI −2.6 to 7.5). Relative to baseline, the
net difference was 3.1 days (95% CI −4.5 to 10.8) more
of drug use last month in the control arm than the inter-
vention arm.
Discussion
The present study suggests that motivational interviewing
combined with treatment as usual to adult patients with
comorbid substance use admitted to a psychiatric emer-
gency unit, may give a sustained reduction in patients’
frequency of substance use at 24 months follow-up com-
pared to treatment as usual only. The reduction the first
12 months of follow-up was similar in the intervention
group and the control group. However, at 24 months the
control group had an increase in frequency of substance
use back to the level at admittance while the intervention
group seemed to manage to stay away from substance use
at a significantly higher degree.
A recent Cochrane review finds an early effect of motiv-
ational interviewing compared to no treatment, reporting
the effect to be strongest post-intervention and weaker at
short and intermediate follow-up. For long term follow-up
the effect was not significant. Compared to treatment as
usual there was no effect in favour of motivational
interviewing [13]. This is in line with the current study
finding no effect of motivational interviewing added to
treatment as usual the first 12 months. However, this study
suggests an effect of motivational interviewing added to
treatment as usual on a long term follow-up. Actually, the
findings of the current study are in accordance with a 3 year
follow-up randomised controlled study where brief inter-
vention (30 minutes) in motivational interviewing style and
treatment as usual compared to treatment as usual only
was delivered to patients with alcohol disorders admitted
to a trauma centre. In that study at 3 year follow-up pa-
tients in the intervention group were less likely to be
arrested for driving under the influence than the control
group [35]. In a randomised controlled study on heavy
drinkers among college students effects were measured
annually for 4 years, showing that the intervention group
receiving brief motivational interviewing reported less
drinking and less negative consequences of drinking also
after 4 years [36]. To our knowledge, randomised con-
trolled trials with long term follow-up on the effect of a
short intervention with motivational interviewing and
treatment as usual compared to treatment as usual are
sparse [13,15,37].The present study indicates that motivational inter-
viewing added to treatment as usual may lead to sustained
protection against substance use relapses in the interven-
tion group compared to the control group at 2 year
follow-up. As motivational interviewing may induce last-
ing intrinsic change in the person it is interesting to look
broader into psychotherapy research on change. In line
with the current study, it has been shown that insight at
the end of short-term dynamic therapy may have a
sustained effect on patients’ change of behavior at 2 years
post treatment [16].
In the present study, there was a reduction in sub-
stance use in both the intervention group and the con-
trol group during the first 12 months after inclusion,
with no substantial difference between the two groups.
One possible explanation for this finding may be that
the patients acutely admitted to a psychiatric emergency
unit are in crisis and have higher levels of substance use
at admission to the hospital than they would usually
have. Thus, regression to the mean may explain some of
the reductions in primary outcome during the first 12 -
months of follow-up. A second explanation may be
linked to the effects of treatment as usual, which might
help recovery and thereby reduce the use of substances
after discharge. A reduction in the use of alcohol has
been found following treatment as usual in patients with
psychotic disorders and alcohol use, typically when in-
volving the use of alcohol assessments [24]. A third mo-
ment is that increased focus on substance use during the
study period may have resulted in a treatment as usual
at the hospital more appropriate for substance use prob-
lems. Also training and supervising therapists in motiv-
ational interviewing during the inclusion period may
have caused a leakage of motivational interviewing ther-
apist style to the treatment as usual group, masking the
possible initial effects of the motivational interviewing
intervention.
The current study has some limitations. One main
limitation in interpreting the difference between the two
groups becoming apparent at 24 months post interven-
tion is the loss to follow-up. At 24 months the follow-up
rate of responders was low (53.3%). There was also a
higher response during follow-up in the intervention
group, and loss to follow-up could possibly have affected
the results and the number of patients included (135)
may be too small to compensate for the mentioned loss
to follow-up. It is also worth to notice that although the
complete case analysis gave comparable results as our
main analysis, the group difference was somewhat
smaller than in the main analysis. However, to partially
compensate for this, we applied a multilevel linear re-
peated measures regression model which uses all avail-
able information and is less susceptible to bias under the
assumption of missing at random [32]. Loss to follow-up
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use admitted to a psychiatric emergency unit, and
conducting studies in this field can be challenging
though not less important since randomised controlled
trials on these patients are still few [24,25]. There were
no statistical significant differences regarding baseline
characteristics (Table 1) between the intervention and
the control group. Looking at baseline characteristics of
responders and non-responders (at 24 months follow-up),
indicated that having a steady income was associated with
higher response rate. This, however, was similar for both
the intervention and the control group and thus is not
expected to have influenced the result.
A second limitation is that the interventions were not
videotaped or recorded. However, they were manual-
guided. Also regular video feedback was arranged to val-
idate the counsellors` motivational interviewing style.
Finally, the self-report questionnaires have not been
assessed for validity or reliability, and self-report ques-
tionnaire only at follow-up is a limitation and it might
have improved the study if biochemical analyses at
follow-up had been performed.
However, several strengths may be mentioned. The
study was a randomised controlled trial performed in a
naturalistic setting representing the daily clinical situ-
ation in a psychiatric emergency unit. The patients were
from both urban and rural areas and the study was
conducted in a single hospital, giving minimal variation
in treatment as usual. The patients were mainly men
and single. Alcohol was the most frequently used sub-
stance. This resembles studies from other countries [2,38].
To compensate for the limitations of self-reporting, urine
screening analyses were performed at baseline.
The patients` psychiatric diagnoses were set at dis-
charge from the department according to ICD-10 Diag-
nostic criteria for research in a consensus meeting with
at least 2 senior consultants. Thus the diagnoses were
not confirmed at admittance and patients not fulfilling
substance use diagnoses at admittance were also eligible
for inclusion. However, 117 of the 135 included patients
received at least one diagnosis of substance use disorder
at discharge, indicating the severity of the substance use
problems for these patients.
Conclusions
The present study suggests that two sessions with motiv-
ational interviewing in addition to treatment as usual to
patients with comorbid substance use admitted to a psy-
chiatric emergency unit may well give substantial reduc-
tion in days of substance use at 24 months follow-up
compared to the group receiving treatment as usual.
The limited duration of stay and the little time available
for intervention are challenges in a psychiatric emergency
unit. This makes short interventions like motivationalinterviewing suitable. Both the intervention group and the
control group showed substantial substance use reduction
during the first 12 months. For the group receiving motiv-
ational interviewing in addition to treatment as usual
however, the study indicates that the reduction may pre-
vail also at 24 months of follow-up, which seems not to be
the case for the group receiving treatment as usual only.
Thus, the present study suggests sustained effects of a
short intervention with motivational interviewing. Further
randomised controlled studies in different psychiatric set-
tings are needed. The studies should have a long term
follow-up beyond 12 months.
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